Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setrusumab in Osteogenesis Imperfecta
NCT05312697Phase 2Terminated
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Apr 2022
- Primary completion
- Jul 2022
- Countries
- 1
01
Overview
A Phase 2 trial of setrusumab in osteogenesis imperfecta (OI), sponsored by Ultragenyx Pharmaceutical Inc.. Started Apr 2022; status: terminated.
02
Drugs
setrusumab
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on NCT05312697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05312697.